Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rongqingbaohuashuan powder + atorvastatin in hyperlipidemia
ChiCTR2400084632Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperlipidemia and carotid atheroma (CAS) comparing Atorvastatin + placebo with Rongqingbaohuashuan powder + atorvastatin (2 arms). Primary endpoint: Blood lipids. Planned start May 2024; status: not yet recruiting.
02
Drugs
atorvastatinRongqingbaohuashuan
03
Conditions
hyperlipidemiacarotid atheroma (CAS)
Beyond the preview
Go deeper on ChiCTR2400084632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084632.